Shen Shouxiang, Li xia, Long Shaohua, Zhao Li, Li Xiaodan
The aim of the study is to optimize the therapeutic dose and time window of picrosede II by orthogonal test in cerebral ischemic injury in rats . Methods, the forebrain ischemia models were established by bilateral common carotid artery occlusion (BCCAO) methods. The successful models were randomly divided into sixtee n groups according to orthogonal experimental design and intervened by injecting pic roside II intraperitonenally at different ischemic time with different dose. The concentratio ns of aquaporins 4 (AQP4), matrix metalloproteinases9 (MMP9) and cyclooxygenase 2 (CO X2) in serum were determined by enzyme linked immunosorbent assay to evaluate the t herapeutic effect of picroside II on cerebral ischemic injury. Results, the best therape utic time window and dose of picroside II in cerebral ischemic injury were (1) ischemia 2.0h wit h 20mg/kg body weight according to the concentration of AQP4; (2) ischemia 1.5h with 20mg/ kg according to the concentrations of MMP9; and (3) ischemia 1.5h with 10 mg/kg according to the concentrations of COX2 in serum. Conclusion, from the principle of lowest therapeuti c dose with longest time window, the optimized therapeutic dose and time window is injec ting picroside II intraperitonenally with 10-20mg/kg body weight at ischemia 1.5-2.0h in cere bral ischemic injury.
Share this article